Zydus has launched Sitaglyn® and Siglyn®, for the management of Type 2 diabetes

Zydus Lifesciences Ltd., a discovery-driven global lifesciences company has launched the molecule Sitagliptin in India under the brand names Sitaglyn® and Siglyn® to address Type 2 diabetes in India. Sitaglyn® and Siglyn® will add on to a comprehensive solution for the management of Type 2 diabetes by providing access to quality care to the patients at an affordable cost, approximately 60% lesser than the originator.

Sitaglyn® and Siglyn® offer an oral solution to the patients providing ease of convenience and better compliance. Sitagliptin is the gold standard in the Dipeptidyl peptidase 4 inhibitor (DPP4i) category with over 62% market share in the global market. The drug provides best in class achievement of Hemoglobin A1C (HbA1c) goals with proven safety profile. With more than 77 million active patients, India is the diabetes capital of the world after China. As per the data, 67% of these patients are unable to achieve their HbA1c goal.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said "The addition of Sitaglyn® and Siglyn® to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes better by making it more affordable. Our high quality product will expand the reach of the molecule to patients in India, supported by our wide distribution network. The drug will help patients achieve their HbA1C goals reducing the disease burden and providing better patient-care and quality of life."

India's oral anti-diabetic market is worth Rs. 125 billion, of which DPP4i class of anti-diabetics has a share of more than Rs. 40 billion. Zydus is amongst the fastest growing players in the diabetes space and has several leading brands to address diabetes including Lipaglyn®, Dapaglyn®, Vinglyn® and Tenglyn®.

With the launch of these brands, Zydus expands its diabetes management offerings for patients and strengthens its presence in the anti-diabetic market.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 365.80 as compared to the previous close of Rs. 367.65. The total number of shares traded during the day was 26125 in over 1289 trades.

The stock hit an intraday high of Rs. 369.50 and intraday low of 364.60. The net turnover during the day was Rs. 9595099.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Sitagliptin India Sitaglyn Siglyn Type2Diabetes